



MOREPEN



Date: 04/12/2024

To,

National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051
Symbol: MOREPENLAB

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400 001
Scrip Code: 500288

Subject: Intimation under Regulations 30 and 30A of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (“SEBI LODR Regulations”) read with Clause 5A, Para A, Part A, Schedule III of the SEBI LODR Regulations.

Dear Sir/ Madam,

This is to inform that the Company has received intimations under Regulation 30A of the SEBI LODR Regulations read with Clause 5A, Para A, Part A, Schedule III of the SEBI LODR Regulations from Dr. Morepen Limited and Morepen RX Limited (Wholly Owned Subsidiaries of the Company) on Wednesday, 4th December 2024.

The necessary disclosures pursuant to SEBI Circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is enclosed herewith as Annexure.

Yours faithfully,

For Morepen Laboratories Limited

Vipul Kumar Srivastava
Company Secretary
F-12148

Encl.: a/a.

Morepen Laboratories Limited

CIN NO. L24231 HP1984PLC006028

Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA
TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA
Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com



MOREPEN



Annexure

Disclosure under Regulations 30 and 30A of the LODR read with Clause 5A, Para A, Part A, Schedule III of the LODR and the circular no. SEBI/ HO/ CFD/ CFD-PoD-1/ P/ CIR/ 2023/ 123 issued by SEBI dated July 13, 2023.

Sr.	Particulars	Details	
a)	if the listed entity is a party to the agreement, i. details of the counterparties (including name and relationship with the listed entity);	The Morepen Laboratories Limited ('MLL') is not party to the agreement.	
b)	if listed entity is not a party to the agreement, i. name of the party entering into such an agreement and the relationship with the listed entity;	Name of parties	Relationship
		Dr. Morepen Limited ('DML')	DML is a related party and wholly owned subsidiary of MLL
		ii. details of the counterparties to the agreement (including name and relationship with the listed entity);	Generica India Limited ('GIL'), is not related to MLL.
	iii. date of entering into the agreement.	4 th December 2024 Effective date – 1 st December 2024.	
c)	Purpose of entering into the agreement;	GIL was acting as distributor for Morepen RX Limited (MRX), a wholly owned subsidiary of the Company in terms of 'Distribution Agreement' dated 15 th February 2024, which is being terminated due to explore better synergies. A new 'Distribution Agreement' is being entered between DML and GIL to explore greater penetration of the products and better Dr. Morepen brand consolidation.	
d)	Shareholding, if any, in the entity with whom the agreement is executed;	MLL does not have any shareholding in GIL.	

Morepen Laboratories Limited

CIN NO. L24231 HP1984PLC006028

Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA
TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA
Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com



e)	Significant terms of the agreement (in brief);	<p>GIL will serve as the distributor for DML's OTC products, pharmaceutical formulations, and other offerings.</p> <p>GIL will purchase the product from DML for resale in the designated territories, marketed under the brand name 'Dr. Morepen,' in accordance with the terms and conditions mutually agreed upon.</p> <p>The Agreement includes standard representations (such as the requisite power and authority to execute and perform required actions, and assurance of non-conflict with other obligations), as well as warranties and covenants. These covenants encompass affirmative, negative, and informational commitments.</p>
f)	Extent and the nature of impact on management or control of the listed entity;	No impact on management or control of MLL.
g)	Details and quantification of the restriction or liability imposed upon the listed entity;	No quantification of the restriction or liability imposed upon the MLL.
h)	Whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship;	Please refer to point (b) i & ii, and (c) <i>supra</i> .
i)	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length".	No, the aforesaid transaction has not been qualified as a related party transaction.
j)	In case of issuance of shares to the parties, details of issue price, class of shares issued;	Not applicable.
k)	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.;	Not applicable.

Morepen Laboratories Limited

CIN NO. L24231 HP1984PLC006028

Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA
TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA
Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com



1)	<p>In case of rescission, amendment or alteration, the listed entity shall disclose additional details to the stock exchange(s):</p> <ul style="list-style-type: none">i. name of parties to the agreement;ii. nature of the agreement;iii. date of execution of the agreement;iv. details and reasons for amendment or alteration and impact thereof (including impact on management or control and on the restriction or liability quantified earlier);v. reasons for rescission and impact thereof (including impact on management or control and on the restriction or liability quantified earlier).	<p>GIL and MRX.</p> <p>Distribution Agreement</p> <p>Executed on 15th February, 2024 (Terminate effective as of 30th November 2024).</p> <p>Not applicable.</p> <p>Please refer point (c), <i>supra</i>;</p> <p>No impact on management or control of MLL or in any manner whatsoever.</p>
----	---	--

Morepen Laboratories Limited

CIN NO. L24231 HP1984PLC006028

Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA
TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA
Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com